__NUXT_JSONP__("/drugs/Parsatuzumab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:b,chebiId:b,chemicalFormula:b,definition:"A humanized IgG1 monoclonal antibody directed against the epidermal growth factor-like domain multiple 7 (EGFL7) with potential antineoplastic activity. Parsatuzumab binds to EGFL7, thereby preventing the activities of EGFL7 on endothelial cells and inhibiting the survival and migration of endothelial cells during angiogenesis. EGFL7, a vascular-restricted extracellular matrix protein which is upregulated during angiogenesis and which regulates vascular development, may be overexpressed on the cell surfaces of various solid tumor cell types.",fdaUniiCode:"435M4HCP2M",identifier:"C90567",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129822","C20401"],synonyms:["Anti-Epidermal Growth Factor-like Domain 7 Monoclonal Antibody MEGF0444A","MEGF 0444A","MEGF0444A","PARSATUZUMAB",a,"RG 7414","RG7414"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FParsatuzumab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Parsatuzumab","","2021-10-30T13:47:10.703Z")));